Sherman speaks with multimedia personality, breast cancer survivor  Lyndsay Levingston. She calls into the K-Zone Morning Kommute to talk about her foundation SurviveHER.

Breast Cancer Survivor Lyndsay Levingston calls into the K-Zone Morning Kommute

BUFFALO, NY- June 8, 2022 – A research paper was recently published in Oncotarget, entitled, “A novel group of genes that cause endocrine resistance in breast cancer identified by dynamic gene expression analysis.”

Breast cancer (BC) is the most common type of cancer diagnosed in women. Among female cancer deaths, BC is the second leading cause of death worldwide.

For estrogen receptor-positive (ER-positive) breast cancers, endocrine therapy is an effective therapeutic approach. However, in many cases, ER-positive tumors become unresponsive to endocrine therapy, and tumor regrowth can occur after treatment. While some genetic mutations contribute to resistance in some patients, the underlying causes of resistance to endocrine therapy are mostly undetermined.

“Endocrine therapies have been successful at improving cancer outcomes; however, the development of endocrine resistance, or resistance to inhibition of ER actions, remains a roadblock in breast cancer treatment.”

In the current study, researchers from UTHealth Houston, University of Chicago, University of Texas MD Anderson Cancer Center, and the University of Houston explored the dynamic behavior of the entire gene population to identify novel genes that play fundamental roles in the development and progression of endocrine-resistant breast cancer.

“In this study, we utilized a recently developed statistical approach to investigate the dynamic behavior of gene expression during the development of endocrine resistance and identified a novel group of genes whose time course expression significantly change during cell modelling of endocrine resistant BC development.”

To better understand the process of acquiring endocrine resistance and its underlying gene expression patterns, the researchers applied their recently developed statistical pipeline to datasets from a public functional genomics repository. They found dynamically regulated genes active in the process of endocrine resistance development and progression. 

Their dynamic gene expression analysis identified 34 novel genes that significantly changed during cell modeling of endocrine-resistant breast cancer development. Expression of a subset of these genes was also differentially expressed in microarray analysis of endocrine-resistant and endocrine-sensitive tumor samples. Surprisingly, a subset of those genes was also differentially expressed in triple-negative breast cancer (TNBC) as compared with ER-positive BC.

“The findings suggest shared genetic mechanisms may underlie the development of endocrine resistant BC and TNBC.”

DOI: https://doi.org/10.18632/oncotarget.28225 

Correspondence to: Michihisa Umetani – mumetani@uh.edu, and Vahed Maroufy – Vahed.Maroufy@uth.tmc.edu 

Special Collection on Breast Cancer: https://www.oncotarget.com/collections/breast-cancer/

Keywords: breast cancer, triple negative breast cancer, gene expression profiling, endocrine resistance, gene clustering

About Oncotarget: Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

To learn more about Oncotarget, visit Oncotarget.com and connect with us on social media:

Twitter – https://twitter.com/Oncotarget 
Facebook – https://www.facebook.com/Oncotarget 
YouTube – www.youtube.com/c/OncotargetYouTube 
Instagram – https://www.instagram.com/oncotargetjrnl/ 
LinkedIn – https://www.linkedin.com/company/oncotarget/ 
Pinterest – https://www.pinterest.com/oncotarget/ 
LabTube – https://www.labtube.tv/channel/MTY5OA
SoundCloud – https://soundcloud.com/oncotarget

For media inquiries, please contact: media@impactjournals.com.

Oncotarget

Press Release: Group of Genes That Cause Endocrine Resistance in Breast Cancer Identified ...

In this episode of the BayCare Clinic podcast, Dr. Natalie Luehmann, breast surgeon with Aurora BayCare General & Vascular Surgery, discusses the impact of specialized and comprehensive breast cancer care for patients. She talks about options available to patients after a breast cancer diagnosis and the approach to collaborative care she and her colleagues take and what impact that has on the patient experience. 

To watch the discussion with Dr. Luehmann, clickhere: https://www.facebook.com/watch/live/?ref=watch_permalink&v=406021157882151
For more information about BayCare Clinic visit: https://baycare.clinic/2SkVAoD
For more information about Aurora BayCare General & Vascular Surgery, visit: https://baycare.clinic/3b1qkI8
For more information about Dr. Natalie Luehmann visit: https://baycare.clinic/3xAZPBg
Find BayCare Clinic on Facebook: https://baycare.clinic/2g4hDFB 
Find BayCare Clinic on Twitter: https://baycare.clinic/2uMlLTW 
Find BayCare Clinic on LinkedIn: https://baycare.clinic/2SkC0Zx 
Find BayCare Clinic on YouTube: https://baycare.clinic/2vGO7YT

Why comprehensive breast cancer care matters

How do you feel  technology has impacted our lives? Tune in as Sarah and Beth discuss the good, bad and the ugly of technology and social media in terms of quality of life.

S3E12: The good (and mostly bad) of technology

Researchers from Eli Lilly and Company published a new research paper in Oncotarget on July 2, entitled, “Continuous treatment with abemaciclib leads to sustained and efficient inhibition of breast cancer cell proliferation.”

Worldwide, breast cancer (BC) is the second most common cancer. Pharmacologically targeting cyclin-dependent kinase 4 and 6 (CDK4 & 6) has proven to be a successful therapeutic approach in patients with estrogen receptor-positive (ER+) breast cancer.

Abemaciclib is the first FDA-approved CDK4 & 6 inhibitor (CDK4 & 6i) approved for the adjuvant treatment of HR+, HER2–, node-positive, early breast cancer (EBC) at high risk of recurrence and a Ki-67 score ≥20%. Differences have been observed in both efficacy and severity of neutropenia among the available CDK4 & 6i, generating interest in a possible mechanistic explanation. In this study, researchers examined the preclinical attributes of abemaciclib and other CDK4 & 6i using biochemical and cell-based assays.

“In vitro, abemaciclib preferentially inhibited CDK4 kinase activity versus CDK6, resulting in inhibition of cell proliferation in a panel of BC cell lines with higher average potency than palbociclib or ribociclib."

Abemaciclib showed activity regardless of HER2 amplification and phosphatidylinositol 3-kinase (PI3KCA) gene mutation status. In human bone marrow progenitor cells, abemaciclib showed lower impact on myeloid maturation than other CDK4 & 6i when tested at unbound concentrations similar to those observed in clinical trials. Continuous abemaciclib treatment provided profound inhibition of cell proliferation, and triggered senescence and apoptosis.

“After continuous dosing with abemaciclib, cells show sustained inhibition of cell proliferation that leads to irreversible effects through apoptosis. These preclinical results support the differentiated safety and efficacy profile of abemaciclib observed in clinical trials.”

DOI: https://doi.org/10.18632/oncotarget.28249

Correspondence to: María José Lallena - Email: lallena_maria_jose@lilly.com 

Special Collection on Breast Cancer: https://www.oncotarget.com/collections/breast-cancer/

Breast Cancer Playlist:
https://www.youtube.com/watch?v=za5mOwlmcFM&list=PL1auE_IUnQH5ja5Ukr9S8FWFcbOqR6NHj

Keywords: abemaciclib, breast cancer, cell lines, CDK4/6, continuous dosing

About Oncotarget: 
Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

To learn more about Oncotarget, visit Oncotarget.com and connect with us on social media:

Twitter - https://twitter.com/Oncotarget
Facebook - https://www.facebook.com/Oncotarget
YouTube – www.youtube.com/c/OncotargetYouTube
Instagram - https://www.instagram.com/oncotargetjrnl/
LinkedIn - https://www.linkedin.com/company/oncotarget/
Pinterest - https://www.pinterest.com/oncotarget/
LabTube - https://www.labtube.tv/channel/MTY5OA
SoundCloud -https://soundcloud.com/oncotarget

For media inquiries, please contact: media@impactjournals.com

Press Release: Continuous Treatment With Abemaciclib and Breast Cancer Cell Proliferation

A new research paper was published in Oncotarget on June 30, 2022, entitled, “Role of germline variants in the metastasis of breast carcinomas.”

Most cancer-related deaths in breast cancer patients are associated with metastasis, a multistep, intricate process that requires the cooperation of tumor cells, tumor microenvironment and metastasis target tissues. It is accepted that metastasis does not depend on the tumor characteristics but the host’s genetic makeup. 

“However, there has been limited success in determining the germline genetic variants that influence metastasis development, mainly because of the limitations of traditional genome-wide association studies to detect the relevant genetic polymorphisms underlying complex phenotypes. “

Full press release: https://www.oncotarget.com/news/pr/oncotarget-role-of-germline-variants-in-the-metastasis-of-breast-carcinomas/

DOI: https://doi.org/10.18632/oncotarget.28250 

Correspondence to: Aurelio A. Moya-García - Email: amoyag@uma.es 

Special Collection on Breast Cancer: https://www.oncotarget.com/collections/breast-cancer/

Sign up for free Altmetric alerts about this article: https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28250

Keywords: breast cancer, germline variants, epistasis, network analysis, seed and soil

About Oncotarget: 

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

To learn more about Oncotarget, visit Oncotarget.com and connect with us on social media:
 
Twitter – https://twitter.com/Oncotarget 
Facebook – https://www.facebook.com/Oncotarget 
YouTube – www.youtube.com/c/OncotargetYouTube 
Instagram – https://www.instagram.com/oncotargetjrnl/ 
LinkedIn – https://www.linkedin.com/company/oncotarget/ 
Pinterest – https://www.pinterest.com/oncotarget/ 
LabTube – https://www.labtube.tv/channel/MTY5OA
SoundCloud – https://soundcloud.com/oncotarget

For media inquiries, please contact: media@impactjournals.com.

Role Of Germline Variants In The Metastasis Of Breast Carcinomas

In this episode Sarah and Beth discuss how stress manifests in their lives and what we can all do to manage our stress better.

S3E13: Stress management

Breast cancer is the most commonly diagnosed cancer among women in Singapore, and it’s the leading cause of cancer death among women worldwide. Breast cancer is a type of cancer that occurs when breast cells grow abnormally and invade surrounding tissue. There are many risk factors for breast cancer, including age, family history, and certain medical conditions. Treatment options include surgery, radiation therapy, hormone therapy, and other therapies. 


There are several things you can do to improve your chances of survival following breast cancer diagnosis. These include regular mammograms, limiting alcohol consumption and avoiding unnecessary exposure to chemicals or radiation, being active throughout the day, maintaining a healthy weight, practicing healthy eating habits, and getting enough sleep on a regular basis.

Your breast specialist doctor Singapore will recommend a treatment plan based on your specific health concerns and personal preferences: https://www.nexussurgical.sg/doctors/dr-tan-yia-swam/

10 Top Tips For Breast Cancer Treatment

Join Sarah and Beth as they talk about philanthropy in the context of quality of life.

S3E14: The power of philanthropy

Join Sarah and Beth as they discuss what thermography is and how some women use it in conjunction with standard imaging.

S3E15: What is Thermography

Nexus Surgical is one of the trusted colorectal cancer diagnostic and treatment centers in Singapore.
There are a number of specialists who focus on the treatment of colorectal cancer. These doctors are typically either surgeons or oncologists, and they work together to provide the best possible care for patients. Surgery is often the first step in treatment, and it is usually followed by chemotherapy and/or radiation therapy. The type of surgery that is performed depends on the stage of the cancer, and the goal is to remove as much of the cancer as possible. chemotherapy and radiation therapy are used to kill any remaining cancer cells and prevent the cancer from returning. Visit a colorectal cancer specialists.

WPKZ 105.3 FM and AM 1280 THE K-ZONE takes its role as a source for local information quite seriously. Through guest appearances, community reminders, local news and sports coverage, we strive to serve the North County. Whether you’re in Leominster, Fitchburg, Townsend, Gardner, Ayer or beyond –  we’re here to serve YOU!

Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Learn from the experts. 
Hear directly from BayCare Clinic® providers on health care questions and topics important to you and your family. Our specialty providers are at the forefront of leading technologies. They’ve got the expertise and the experience necessary to be your leading health care resource. 
Our medical experts are here to answer all your burning questions. In addition to overall health and wellness topics, we will cover topics like innovations in health care, preventative models of care and the changing landscape of health and wellness as we know it.  
BayCare Clinic is the largest physician-owned specialty-care clinic in northeastern Wisconsin and Michigan’s Upper Peninsula. It is based in Green Bay, Wisconsin. BayCare Clinic offers expertise in more than 20 specialties, with more than 100 physicians serving in 16 area communities. BayCare Clinic is a joint partner in Aurora BayCare Medical Center, a 167-bed, full-service hospital. 
Our podcasts are intended for informational purposes only. The information in our podcasts should not be relied upon as medical advice. They are not designed to replace an appointment with your primary care physician or a specialty provider.  Always consult first with your physician about anything related to your personal health.

This podcast is for breast cancer patients who feel isolated or sad and want a friend but don't feel up to talking with anyone. With Sarah and Beth, you'll get friendship and validation with zero expectations or judgment.

New tracks tagged #BREASTCANCER